The hepatitis C study most often cited in cannabis literature examined whether cannabis helped patients stay on interferon treatment. That is a real study with a real finding. It is also a study about a treatment that has been almost entirely replaced: modern hepatitis C therapy cures more than 95% of patients, usually in 8 to 12 weeks, with few side effects. An article that quotes the 2006 result without saying that is describing a problem that has largely been solved.
Nothing here is medical advice and nothing here is a reason to change antiretroviral therapy or to delay hepatitis C treatment. Both conditions have highly effective treatments, and adherence to them is what determines outcomes. In Thailand cannabis flower is a controlled herb dispensed only on prescription form PT 33 by an authorised practitioner.
1. Hepatitis C: A Correct Finding About an Obsolete Problem
The study cited is real. Sylvestre and colleagues followed 71 recovering substance users treated with interferon and ribavirin at a Northern California clinic. They reported the results in the European Journal of Gastroenterology and Hepatology in October 2006. The 22 cannabis users were more likely to stay on treatment for the planned course. More of them also achieved a sustained virological response (SVR, effectively a cure): 54% against 18% of non-users. The lead researcher, Dr Diana Sylvestre of the University of California, San Francisco, said the benefit came through adherence: cannabis may have helped patients cope with a punishing regimen. It was explicitly not an antiviral effect.
That SVR result is the headline of the paper, and anyone who checks the source will find it. It needs reading in context. The study was small and observational, cannabis use was self-reported, and the group was too small for full statistical adjustment. The better cure rate is explained by more patients finishing treatment, not by anything cannabis did to the virus.
What has changed since is everything else. Interferon-based therapy meant months of injections, with flu-like symptoms, fatigue, insomnia, appetite loss, nausea, muscle and joint pain and depression. Patients dropped out, and anything that helped them finish mattered a great deal.
The World Health Organization now recommends pan-genotypic direct-acting antivirals (DAAs) for all adults, adolescents and children aged three and over. Interferon-free regimens were first approved in 2013–14. They are taken as tablets for 8–12 weeks for most regimens, and longer in some cases of cirrhosis or genotype 3. Side effects are few, and DAAs cure more than 95% of people with hepatitis C. Generics have brought costs down sharply. In 2021, WHO said low- and middle-income countries could aim for as little as US$60 per 12-week course of generic sofosbuvir with daclatasvir. The prices countries actually pay still vary widely. In Thailand, published reports say sofosbuvir/velpatasvir was added to the Universal Coverage benefit package in 2021. Ask a public hospital about current eligibility.
The WHO’s latest estimates are for 2024 (Global Hepatitis Report 2026). They put the global burden at about 47 million people living with chronic hepatitis C, about 0.9 million new infections that year and roughly 240,000 deaths, mostly from cirrhosis and liver cancer.
So the honest reading of the 2006 finding today is that it is an interesting piece of history from the interferon era, not a current indication. The side-effect burden it addressed largely no longer exists. For someone with hepatitis C in 2026, the priority is diagnosis and access to DAAs, which cure the infection. Support for tolerating a superseded regimen is no longer the issue.
Does cannabis harm the liver in hepatitis C? This is the question the rest of the literature actually asks. Early cross-sectional studies linked daily cannabis use to faster fibrosis. Studies of that kind look at people at one moment and cannot show which came first. A stronger prospective study, Kelly and colleagues (Clinical Infectious Diseases, 2016), followed 575 women with HIV and hepatitis C in the Women’s Interagency HIV Study for a median of 11 years. Cannabis use was not associated with progression to significant fibrosis, even among daily users. Alcohol was. That is reassuring on one narrow point. It does not make cannabis a hepatitis treatment.
Hepatitis B is a different disease. Chronic hepatitis B is common across Thailand and Southeast Asia, and the cure described above does not apply to it. Current drugs cannot cure chronic HBV. It is controlled with long-term antivirals such as tenofovir or entecavir, plus regular liver-cancer screening. No cannabis product replaces either.
One caveat survives the change in treatment. Several DAAs are affected by liver enzyme or transporter interactions, and cannabinoids interact with cytochrome P450 enzymes. Anyone on DAA therapy should tell the treating team what else they are taking.
2. HIV: Where the Evidence Is Better
Here the picture is more favourable, because the indications are symptomatic and the trials were properly controlled, although they were small.
Neuropathic pain. HIV-associated sensory neuropathy is common and painful, and existing drugs often help poorly. Abrams and colleagues (Neurology, 2007) ran a 5-day inpatient trial in which 50 patients completed treatment. Smoked cannabis three times daily gave a 34% median reduction in daily pain, against 17% on placebo. The authors concluded that smoked cannabis was well tolerated and relieved this pain, with effects comparable to oral drugs used for chronic neuropathic pain. Ellis and colleagues (Neuropsychopharmacology, 2009) ran a crossover trial with 28 completers. They found that smoked cannabis reduced pain more than placebo when added to stable concomitant analgesics.
Note the framing, which is explicit in Ellis: cannabis was added to existing analgesia, in patients whose pain was not controlled. This is the same positioning as the neuropathic pain evidence discussed in a separate forum article on chronic pain. It makes neuropathic pain one of the better-supported indications in the cannabis literature. Both trials were small and short, however, so the evidence is promising rather than settled.
Appetite and weight. In 2017 the US National Academies of Sciences, Engineering and Medicine (NASEM) found limited evidence that cannabis and oral cannabinoids increase appetite and reduce weight loss associated with HIV/AIDS. “Limited” is a specific grade, not a dismissal. It is still well below the grades the same review gave to chronic pain in adults (“substantial”) and to oral cannabinoids for chemotherapy-induced nausea (“conclusive”). The difference between anorexia and cachexia is covered in a separate forum article on appetite loss and cachexia.
Dronabinol (synthetic THC) has its own history here. It was first approved in 1985 for chemotherapy-induced nausea and vomiting, and its indication was extended in 1992 to AIDS-related anorexia with weight loss. Both dates fall before effective antiretroviral therapy arrived in 1996, when AIDS wasting was common and often fatal. It is an appetite indication and does not act on the virus. The population that generated the evidence is not the population living with HIV today.
3. The Context That Reframes Everything
Effective antiretroviral therapy changed HIV from a fatal illness into a manageable chronic condition, and it changed what patients need. The older argument for cannabis was about AIDS wasting and unaffordable patented drugs. That was a real access-to-medicines controversy, but it is a justice question, not a clinical case for cannabis.
Today the determinant of outcome in HIV is adherence to antiretroviral therapy, sustained over decades. Anything that supports adherence helps; anything that undermines it is dangerous whatever else it does. Observational work on cannabis and adherence has pointed in both directions, which is a reason for the treating clinician to know rather than guess.
The interaction question is also real. Dronabinol is metabolised mainly by CYP2C9 and CYP3A4, and THC and CBD in other products also go through the cytochrome P450 system. Several antiretrovirals are potent inhibitors or inducers of these enzymes, especially CYP3A4. Adding cannabis or a cannabinoid can therefore change drug levels, and in ART levels matter a great deal. A separate forum article on drug interactions covers the mechanism. None of this is a reason to hide cannabis use from an HIV clinician. It is the reason to disclose it.
4. Personal Accounts, Read Properly
Personal stories circulate widely. In them, people living with HIV describe cannabis restoring appetite and weight, or letting them “reduce their reliance on medication”. Such accounts can matter to the people telling them. They are still subject to every filter discussed in a separate forum article on why personal testimony is not medical evidence. Most importantly, the person was almost always on antiretroviral therapy too, and the two effects cannot be separated.
The phrase “reduce reliance on medication” needs particular care. In HIV, reliance on medication is not a burden to minimise. It is the treatment that keeps the virus suppressed. Read any account that treats reducing it as the goal with that fact in mind.
5. Where This Leaves Things
| Indication | Status |
|---|---|
| HIV-associated neuropathic pain | Two small randomised trials (n=50, 5 days; n=28, crossover) showing benefit, explicitly as an add-on in Ellis. Among the better evidence in the field |
| Appetite and weight in HIV/AIDS | Limited evidence (NASEM 2017). Basis of dronabinol’s 1992 AIDS-anorexia indication, from the pre-ART era |
| Hepatitis C treatment adherence | 2006 observational finding about interferon: better retention and SVR among cannabis users, attributed to adherence. Interferon has largely been replaced by DAAs, which cure >95%, usually in 8–12 weeks |
| Liver fibrosis in HIV/HCV co-infection | No association with cannabis in a 575-woman prospective cohort (Kelly 2016). Alcohol was associated |
| Antiviral effect against HIV, HCV or HBV | None. The hepatitis C researchers said so explicitly |
6. In Thailand
Cannabis flower is a controlled herb under the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis) B.E. 2568, issued 26 June 2025. It may be dispensed only on prescription form PT 33 from an authorised practitioner, for no more than 30 days per prescription. Each prescription can be used once, with no refills, and flower must come from a GACP-certified site. Online sale and advertising of flower are prohibited, and recreational use is not permitted. Separately, health claims for products are regulated by product category under the Drug Act B.E. 2510, the Herbal Products Act B.E. 2562 and the Food Act B.E. 2522. Advertising a product as treating HIV or hepatitis is therefore both unsupported and legally risky. The Cannabis Control Act is still a draft: the Cabinet approved it on 22 September 2026 and sent it to the House. Forum topics 1293 and 1330 cover the legal framework in more detail.
For anyone living with HIV, the interaction question makes prescriber and pharmacist involvement essential rather than optional. For anyone with hepatitis C, the priority is access to DAA treatment, which is curative. Anyone with hepatitis B needs long-term monitoring and treatment.
If you are living with HIV in Thailand or the region and have discussed cannabis with your HIV clinician: were interactions with your antiretrovirals actually checked, and by whom, the doctor or the pharmacist? That check is the single most useful thing in this whole article and the one most likely to be skipped.
References
- Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. Eur J Gastroenterol Hepatol. 2006;18(10):1057–1063.
- Abrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–521.
- Ellis RJ, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–680.
- Kelly EM, et al. Marijuana use is not associated with progression to advanced liver fibrosis in HIV/hepatitis C virus–coinfected women. Clin Infect Dis. 2016;63(4):512–518.
- National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017.
- World Health Organization. Updated recommendations on HCV treatment, simplified service delivery and diagnostics. 2022.
- World Health Organization. Hepatitis C fact sheet (2026 update) and Global Hepatitis Report 2026.
- World Health Organization. News release on access to hepatitis C diagnostics and treatment in low- and middle-income countries, 27 January 2021.
- Dronabinol (Marinol) US prescribing information; “Dronabinol”, StatPearls, NCBI Bookshelf.
General information, not medical advice. Never reduce or interrupt antiretroviral therapy, and do not delay hepatitis C treatment: it is curable.